Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta (Aβ) plaques and neurofibrillary tangles. The humanized monoclonal antibody solanezumab was designed to increase the clearance from the brain of soluble Aβ, peptides that may lead to toxic effects in the synapses and precede the deposition of fibrillary amyloid. METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving patients with mild dementia due to Alzheimer's disease, defined as a Mini-Mental State Examination (MMSE) score of 20 to 26 (on a scale from 0 to 30, with higher scores indicating better cognition) and with amyloid deposition shown by means of florbetapir positron-emission tomography or Aβ1-42 measurements in cerebrospinal fluid. Patients were randomly assigned to receive solanezumab at a dose of 400 mg or placebo intravenously every 4 weeks for 76 weeks. The primary outcome was the change from baseline to week 80 in the score on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; scores range from 0 to 90, with higher scores indicating greater cognitive impairment). RESULTS: A total of 2129 patients were enrolled, of whom 1057 were assigned to receive solanezumab and 1072 to receive placebo. The mean change from baseline in the ADAS-cog14 score was 6.65 in the solanezumab group and 7.44 in the placebo group, with no significant between-group difference at week 80 (difference, -0.80; 95% confidence interval, -1.73 to 0.14; P=0.10). As a result of the failure to reach significance with regard to the primary outcome in the prespecified hierarchical analysis, the secondary outcomes were considered to be descriptive and are reported without significance testing. The change from baseline in the MMSE score was -3.17 in the solanezumab group and -3.66 in the placebo group. Adverse cerebral edema or effusion lesions that were observed on magnetic resonance imaging after randomization occurred in 1 patient in the solanezumab group and in 2 in the placebo group. CONCLUSIONS: Solanezumab at a dose of 400 mg administered every 4 weeks in patients with mild Alzheimer's disease did not significantly affect cognitive decline. (Funded by Eli Lilly; EXPEDITION3 ClinicalTrials.gov number, NCT01900665 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the expedition3 trial (NCT01900665), aimed at further validating the drug’s efficacy in patients with mild AD, the drug was declared unsuccessful in 2016, as it failed to meet its primary endpoints.457–459”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [459]
In the citing paper
“In three completed phase 3 clinical trials (EXPEDITION, EXPEDITION2, EXPEDITION3), solanezumab did not significantly reduce the decline in cognition or function (e.g., activities of daily living and community involvement) in patients who had received a clinical diagnosis of mild-to-moderate AD [79].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [79]
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [46]
In the citing paper
“anti-Aβ mAbs that predominantly bind to monomeric Aβ do not mediate substantial removal of plaque and lack clinical efficacy”
From The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics (2022) · cites this paper as [42]
In the citing paper
“A third phase 3 trial in mild AD also failed to demonstrate a significant benefit on the primary endpoint (Honig et al., 2018).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Honig et al., 2018
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Measurement of Functional Activities in Older Adults in the Community
Pfeffer, R. I., Kurosaki, T. T., Harrah, C. H., Chance, J. M., & Filos, S. (1982) · Journal of Gerontology · doi:10.1093/geronj/37.3.323 · Cited by 2,972
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 501–600 of 999
Attention-guided neural network for early dementia detection using MRS data
kherchouche, A., Ahmed, O. B., Guillevin, C., Tremblais, B., Julian, A., Fernández-Maloigne, C., & Guillevin, R. (2022) · Computerized Medical Imaging and Graphics · doi:10.1016/j.compmedimag.2022.102074 · Cited by 18
Disease progression model using the integrated Alzheimer's Disease Rating Scale
Gueorguieva, I., Chua, L., Willis, B. A., Sims, J. R., & Wessels, A. M. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12876 · Cited by 19
Mohanty, M., & Kumar, P. (2022) · Geriatrics · doi:10.3390/geriatrics8010004 · Cited by 23
“treatments in dementia or mild cognitive impairment (MCI) stages failed [10,11].”
BackgroundAlzheimer's Disease - A Comprehensive Review
Woźniak, K., Gardian-Baj, M., Jung, M., Hedesz, P., Jung, M., Żuk‐Łapan, A., Doryń, A., Jędral, K., Włodarczyk, A., Szczerbiak, A., et al. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.56.013 · Cited by 21
“[24]”
Amyloid‐β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects
Yu, Y., Yu, S., Battaglia, G., & Tian, X. (2024) · Ibrain · doi:10.1002/ibra.12155 · Cited by 38
“Solanezumab 142,143 : This is a human IgG1 monoclonal antibody, which targets the central region of A β and recognizes soluble monomeric A β ; it could increase the A β levels in plasma and CSF in a dose ‐ dependent manner.”
BackgroundDisease Modification in Alzheimer’s Disease: Current Thinking
Liu‐Seifert, H., Schumi, J., Miao, X., Tian, Y., Rabbia, M. A., Andersen, S. W., Wilson, S., Li, W., & Entsuah, R. (2020) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-019-00068-4 · Cited by 18
“As shown in EXPEDITION3, the ADAS-Cog followed a nonlinear curve over time.(18) The EPOCH trial(21) provides another example of a nonlinear shape to the ADASCog over the trial course.”
MethodSelf-citationFranco, R., Navarro, G., & Martínez‐Pinilla, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133297 · Cited by 18
“Apart from the fact that GBA1 has no proteolytic activity, it remains to be elucidated whether clearing Lewy bodies or neurofibrillary tangles will lead to similar failures as those obtained in the case of therapies addressed to clear β-amyloid-containing plaques in AD patients [4,65,66].”
ResultSharma, A., & Goyal, R. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172892 · Cited by 20
Garibotto, V., Albert, N. L., Barthel, H., van Berckel, B. N. M., Boellaard, R., Brendel, M., Cecchin, D., Ekmekçioğlu, Ö., van de Giessen, E., Guedj, É., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05485-y · Cited by 18
“, bapineuzumab [17], solanezumab [18], or crenezumab [19], some more recently developed molecules have shown larger effects on amyloid load including aducanumab [20], donanemab [21], gantenerumab [22], and lecanemab [23].”
BackgroundBumber, J. R., Rački, V., Mežnarić, S., Pelčić, G., & Mršić‐Pelčić, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176047 · Cited by 24
You, M., Wang, K., Pan, Y., Tao, L., Ma, Q., Zhang, G., & Hu, F. (2022) · Food & Function · doi:10.1039/d1fo02397g · Cited by 20
Zhang, Y., Li, H., & Zheng, Q. (2023) · European Radiology · doi:10.1007/s00330-023-09519-x · Cited by 19
“The MMSE and ADAS13 scores have been widely used to monitor the AD progression [25, 32, 33].”
Ali, S. A., Chung, K. H. K., Forgham, H., Olsen, W. P., Käkinen, A., Balaji, A., Otzen, D. E., Davis, T. P., & Javed, I. (2023) · Advanced Science · doi:10.1002/advs.202301423 · Cited by 18
Yan, C., Wang, Y., Ma, Y., Liu, H., Tang, S., Li, Y., Shi, J., Ding, S., & Lyu, Z. (2024) · Materials Today Chemistry · doi:10.1016/j.mtchem.2024.102222 · Cited by 20
Qi, X., Nizamutdinov, D., Yi, S. S., Wu, E., & Huang, J. H. (2024) · Biomedicines · doi:10.3390/biomedicines12112636 · Cited by 19
Meyer, P., McSweeney, M., Gonneaud, J., & Villeneuve, S. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.05.001 · Cited by 22
Informed consent, therapeutic misconception, and clinical trials for Alzheimer's disease
Wilkins, J. M., & Forester, B. P. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5262 · Cited by 17
Pharmakologische Therapie der Alzheimer-Demenz: Aktueller Stand und Perspektiven
Müller, P., Fendt, M., & Müller, N. (2019) · Der Internist · doi:10.1007/s00108-019-0625-4 · Cited by 19
Shimada, H., Minatani, S., Takeuchi, J., Takeda, A., Kawabe, J., Wada, Y., Mawatari, A., Watanabe, Y., Shimada, H., Higuchi, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124443 · Cited by 17
“Previous clinical trials targeting accumulated Aβ were mostly successful in reducing Aβ but failed to improve the clinical outcomes and even worsened the outcomes in some studies [18].”
BackgroundPourhamzeh, M., Joghataei, M. T., Mehrabi, S., Ahadi, R., Hojjati, S. M. M., Fazli, N., Nabavi, S. M., Pakdaman, H., & Shahpasand, K. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00906-2 · Cited by 20
RetractedTatiparti, K., Sau, S., Rauf, M. A., & Iyer, A. K. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.09.025 · Cited by 16
Searching the Dark Genome for Alzheimer’s Disease Risk Variants
Raybould, R., & Sims, R. (2021) · Brain Sciences · doi:10.3390/brainsci11030332 · Cited by 19
“However, recent failures in clinical trials, based on removing either soluble and/or insoluble Aβ or targeting enzymes responsible for cleavage of APP, have thrown doubt on the hypothesis [4,5].”
BackgroundLi, H., Uittenbogaard, M. N., Hao, L., & Chiaramello, A. (2021) · Metabolites · doi:10.3390/metabo11040233 · Cited by 20
Mechanistic insight into inhibition of amyloid fibrillation of human serum albumin by Vildagliptin
Malik, S., Zaidi, N., Siddiqi, M. K., Majid, N., Masroor, A., Salam, S., & Khan, R. H. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112563 · Cited by 18
Chundu, U. C., Thiriveedhi, S. R., Bhatti, C., Mupparaju, J. S., Otinashvili, N., & Gelishvili, E. (2025) · Cureus · doi:10.7759/cureus.85377 · Cited by 17
Advancements in the treatment of Alzheimer's disease: a comprehensive review
Rajanna, S., Gundale, P. P., & Mahadevaiah, A. D. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0204 · Cited by 22
“Moreover, cognitive training may enhance the brain’s plasticity, helping it to adapt and compensate for neuronal damage 22 .”
Histidine Tautomeric Effect on the Key Fragment R3 of Tau Protein from Atomistic Simulations
Li, H., Li, N., Tang, Y., & Lee, J. Y. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00093 · Cited by 16
A review of therapeutic failures in late-stage clinical trials
Jain, R., Subramanian, J., & Rathore, A. S. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2161366 · Cited by 25
“Still, it failed to reach the primary endpoint [37].”
BackgroundJi, Y., Yang, C., Pang, X., Yan, Y., Wu, Y., Geng, Z., Hu, W., Hu, P., Wu, X., & Wang, K. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01201 · Cited by 22
“Although clinical trials have rarely shown their effectiveness or exacerbated the deterioration of cognition (Honig et al., 2018; Egan et al., 2019; Selkoe, 2019), rTMS may be an early intervention to inhibit the production of these pathogenic proteins with enhanced cognitive function (Chen et al.,…”
Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets
Gu, X., Long, Q., Qi, Q., Zhou, J., Chen, S., & Wang, L. (2024) · BioScience Trends · doi:10.5582/bst.2023.01288 · Cited by 18
Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 20
Now and future: Strategies for diagnosis, prevention and therapies for Alzheimer’s disease
Shi, J., Touchon, J., Middleton, L. T., Boada, M., Vassar, R. J., Vellas, B. J., & Shen, Y. (2024) · 中国科学通报:英文版 · doi:10.1016/j.scib.2024.09.042 · Cited by 17
Self-citationTransgenerational Interaction of Alzheimer’s Disease with Schizophrenia through Amyloid Evolvability
Takamatsu, Y., Ho, G. J., Waragai, M., Wada, R., Sugama, S., Takenouchi, T., Masliah, E., & Hashimoto, M. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180986 · Cited by 18
“cacy [43], and, on a cautious note, it was recently 325 reported that an ongoing early phase II trial using the 326”
BackgroundSmith, J. W., Jiang, X., An, H., Barclay, A. M., Licari, G., Tajkhorshid, E., Moore, E. G., Rienstra, C. M., Moore, J. S., & Chen, Q. (2019) · ACS Applied Nano Materials · doi:10.1021/acsanm.9b01331 · Cited by 16
Immunotherapy Targeting Amyloid-ß Peptides in Alzheimer’s Disease
Zampar, S., & Wirths, O. (2020) · Exon Publications eBooks · doi:10.36255/exonpublications.alzheimersdisease.2020.ch2 · Cited by 27
“As a result, the secondary analyses of the previous EXPEDITION trials were not reproduced and solanezumab showed no benefit with regard to cognitive decline in patients with mild AD (107).”
ResultHu, N., Mackey, H. M., & Thomas, R. G. (2021) · Biometrical Journal · doi:10.1002/bimj.202000184 · Cited by 17
“The sample size of 100 aims to reflect a potential Phase II Alzheimer’s disease (AD) trial (Salloway et al., 2018; Cummings et al., 2018), and the size of 500 reflects a potential Phase III AD trial (Honig et al., 2018; Ostrowitzki et al., 2017).”
The Development of Pharmacological Therapies for Alzheimer’s Disease
Ping, L., Sun, J., Cheng, Q., Yang, Y., Cordato, D. J., & Gao, J. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00282-z · Cited by 17
“Disappointingly, EXPEDITION3 failed to show a similar cognitive benefit [24].”
BackgroundZhang, X., Huai, Y., Cai, J., Song, C., & Zhang, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.014 · Cited by 17
Analysis of risk factors for depression in Alzheimer’s disease patients
Yang, H., Hong, W., Chen, L., Tao, Y. K., Peng, Z., & Zhou, H. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1730369 · Cited by 19
Sheng, L., Cao, W., Lin, P., Chen, W., Xu, H., Zhong, C., Yuan, F., Chen, H., Li, H., Liu, C., et al. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s296197 · Cited by 16
Benign and malignant scientific irreproducibility
Fiala, C., & Diamandis, E. P. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.03.015 · Cited by 19
Wang, Y., Yu, Q., Chen, B., Zhou, J., Li, Z., Liao, W., Liu, J., & Yang, A. (2025) · BMC Neurology · doi:10.1186/s12883-025-04302-5 · Cited by 17
“For moderate to severe ARIA-E, more aggressive interventions may be required, such as the use of diuretics or glucocorticoids to alleviate cerebral edema [22, 23], and in some cases, discontinuation of anti-Aβ monoclonal antibody therapy may be necessary [24].”
Towards pharmacological prevention of Alzheimer disease
Llibre‐Guerra, J. J., McDade, E., Schindler, S. E., Clifford, D. B., Supnet, C. B., Atri, A., & Bateman, R. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01154-y · Cited by 20
Serrano‐Pozo, A., Escott‐Price, V., Grinberg, L. T., Pascoal, T. A., Suárez‐Calvet, M., Dubois, B., & Sperling, R. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00198-4 · Cited by 21
Meyer, P., Savard, M., Poirier, J., Morgan, D., Breitner, J. C. S., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.007 · Cited by 16
A Review of APOE Genotype-Dependent Autophagic Flux Regulation in Alzheimer’s Disease
Chen, H., Chen, F., Zhang, M., Chen, Y., Cui, L., & Liang, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210602 · Cited by 15
Cogo‐Moreira, H., Krance, S. H., Wu, C., Lanctôt, K. L., Herrmann, N., Black, S. E., MacIntosh, B. J., Rabin, J. S., Eid, M., Swardfager, W., et al. (2023) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12376 · Cited by 21
New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Chen, H., Xu, J., Xu, H., Luo, T., Li, Y., Jiang, K., Shentu, Y., & Tong, Z. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041133 · Cited by 17
Lyu, D., Lyu, X., Huang, L. T., & Fang, B. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101959 · Cited by 15
ten Kate, M., Barkhof, F., & Schwarz, A. J. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.92 · Cited by 15
Kim, J., Jeon, H., Kim, H. Y., & Kim, Y. S. (2023) · ChemBioChem · doi:10.1002/cbic.202300328 · Cited by 17
Recent Advancements in the Treatment of Alzheimer’s Disease: A Multitarget-directed Ligand Approach
Kumar, S., Mahajan, A. T., Ambatwar, R., & Khatik, G. L. (2023) · Current Medicinal Chemistry · doi:10.2174/0109298673264076230921065945 · Cited by 18
Liao, Z., Zhang, Q., Ren, N., Zhao, H., & Zheng, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418939 · Cited by 17
Exploring the Potential of Neuroproteomics in Alzheimer's Disease
Uddin, M. S., Kabir, M. T., Jakaria, M., Sobarzo‐Sánchez, E., Barreto, G. E., Perveen, A., Hafeez, A., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200603112030 · Cited by 17
Sun, P., Hu, Y., Xing, Q., Deng, W., Ou, Y., Pan, G., Zhong, X., & Hu, W. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00073 · Cited by 15
Anti-Inflammatory Agents: An Approach to Prevent Cognitive Decline in Alzheimer’s Disease
Brod, S. A. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215125 · Cited by 18
The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer’s disease
Zhao, X., Li, X., She, L., Li, L., Huang, P. C., & Liang, G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113188 · Cited by 17
Gregory, S., Saunders, S., & Ritchie, C. W. (2022) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(22)00219-7 · Cited by 18
“For example, although trials have shown the efficacy of certain compounds in clearing amyloid, 38,39,53 research on the effect that normalising amyloid has on tau pathology, and whether effects differ by sex or APOE ε4 status, has not been done.”
BackgroundResultFDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease
Høilund‐Carlsen, P. F., Revheim, M.-E. R., Alavi, A. A., & Barrio, J. R. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004710 · Cited by 16
Arbo, B. D., Ribeiro, M. F. M., & García‐Segura, L. M. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100943 · Cited by 16
A Systematic Review on the Feasibility of Salivary Biomarkers for Alzheimer's Disease
Bouftas, M. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.57 · Cited by 17
“After undergoing phase III trials, it was concluded that neither drug significantly affected cognitive decline [4,11].”
Singh, P. K., Badimon, A., Chen, Z., Strickland, S., & Norris, E. H. (2021) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12504 · Cited by 20
Therapeutic news in Alzheimer’s disease: Soon a disease-modifying therapy?
Villain, N. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.02.456 · Cited by 14
Forlenza, O. V., & Barbosa, B. J. A. P. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2025-e001 · Cited by 22
Anti-amyloid monoclonal antibody therapies in Alzheimer’s disease – a scoping review
Elamin, S. A., Shibli, A. N. A., Shaito, A. A., Al-Maadhadi, M., Zolezzi, M., & Pedersen, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.011 · Cited by 19
Lou, C., Habes, M., Illenberger, N., Ezzati, A., Lipton, R. B., Shaw, P. A., Stephens‐Shields, A. J., Akbari, H., Doshi, J. J., Davatzikos, C. A., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab264 · Cited by 15
KIBRA regulates amyloid β metabolism by controlling extracellular vesicles secretion
Han, X., Wang, C., Song, L., Wang, X., Tang, S. H., Hou, T., Liu, C., Liang, X., Qiu, C., Wang, Y., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103980 · Cited by 15
Seibyl, J. P. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264773 · Cited by 18
“The result was the unusual circumstance of use of 2 investigational drugs in the same trial, even as both were in early-to mid-development phases ( 20 ).”
BackgroundDanziger, R., Fuchs, D.-T., Koronyo, Y., Rentsendorj, A., Sheyn, J., Hayden, E. Y., Teplow, D. B., Black, K. L., Fuchs, S., Bernstein, K. E., et al. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1179315 · Cited by 16
Updates on pharmacological treatment for Alzheimer’s disease
Tipton, P. W. (2024) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.96286 · Cited by 17
Targeting the molecular web of Alzheimer’s disease: unveiling pathways for effective pharmacotherapy
Jadhav, D., Saraswat, N., Vyawahare, N. S., & Shirode, D. S. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00775-8 · Cited by 19
“Senile plaques are created when these monomers oligomerize and agglomerate [139].”
BackgroundA case for seeking sex-specific treatments in Alzheimer’s disease
Lynch, M. A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1346621 · Cited by 20
“Among others in trial are solanezumab, which targets the mid-domain of the A β peptide and recognizes soluble monomeric A β (Doody et al., 2014; Honig et al., 2018), crenezumab, which binds to stable oligomers and inhibits aggregation of A β (Ostrowitzki et al., 2022), ganteneumab, which binds to a…”
BackgroundAdvances of therapy for Alzheimer's disease: An updated review
Mei, C., Zhan, J., Zhu, S., Zhang, Y., Xiong, C., Wang, J., Xu, Y. J., Zhong, H., & Cheng, J. (2024) · Brain‐X · doi:10.1002/brx2.68 · Cited by 16
Wang, L., Wei, Y., Sun, Z., Tai, W., Li, H., YaLing, Y., Jiang, L., & Wang, J. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14886 · Cited by 15
“…extracellular β - amyloid (A β ) deposition, 4 and neurofibrillary tangles formed by intracellular hyper-phosphorylated tau protein aggregation in neuron 5 are two hallmark pathological changes in the brains of AD patients, and they also represent key factors inducing or mediating cognitive damage.”
Alzheimer’s disease and immunotherapy
Qin, W., Pang, Y., Nie, S., Quan, M., & Jia, J. (2024) · Current Medicine · doi:10.1007/s44194-024-00035-8 · Cited by 16
Passive Anti-amyloid Beta Monoclonal Antibodies: Lessons Learned over Past 20 Years
Wicker, A., Shriram, J., Decourt, B., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00664-z · Cited by 18
“At the conclusion of the study, ADAS-cog14 scores were not improved, but ADCS-ADL scores were slightly significantly in favor of the experimental group [22].”
Jeremic, D., Navarro‐López, J. D., & Jiménez‐Díaz, L. (2025) · Journal of Medical Internet Research · doi:10.2196/68454 · Cited by 20
“Our analysis included aducanumab [15], lecanemab [16], bapineuzumab [17,18], and solanezumab [19,20], showing that aducanumab and lecanemab produced the most promising cognitive, functional, and biomarker results.”
InfluentialLee, W. J., Ham, S. A., Lee, G. H., Choi, M., Yoo, H., Paek, K. S., Lim, D., Hong, K., Hwang, J. S., & Seo, H. G. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14715 · Cited by 14
Wang, Z., Cao, M., Xiang, H., Wang, W., Feng, X., & Yang, X. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00409 · Cited by 15
Wang, H., Li, L., Jia, K., Wang, Q., Sui, S., Lin, Y., & He, Y. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001526 · Cited by 14
Gauba, E., Sui, S., Tian, J., Driskill, C. M., Jia, K., Yu, C., Rughwani, T., Wang, Q., Kroener, S., Guo, L., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.09.018 · Cited by 15
Shi, M., Chu, F., Tian, X., Aerqin, Q., Zhu, F., & Zhu, J. (2021) · The Neuroscientist · doi:10.1177/1073858420987224 · Cited by 17
Utomo, R. Y., Asawa, Y., Okada, S., Ban, H. S., Yoshimori, A., Bajorath, J., & Nakamura, H. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116357 · Cited by 15
Chen, Y., & Colonna, M. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102233 · Cited by 14
Setbacks and promises for drugs against Alzheimer's disease
Rinaldi, A. C. (2018) · EMBO Reports · doi:10.15252/embr.201846714 · Cited by 14
“At the same time, Eli Lilly published the last round of data that brought it to abandon development of solanezumab, a monoclonal antibody designed to target b-amyloid protein, that failed to improve cognition in patients with mild Alzheimer’s disease [4].”
BackgroundAD molecular: Imaging tau aggregates with positron emissions tomography
Betthauser, T. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.007 · Cited by 15
Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Kile, S. J., Au, W. J., Parise, C. A., Sohi, J., Yarbrough, T. L., Czeszynski, A., Johnson, K., Redline, D., Donnel, T., Hankins, A. I., et al. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519899800 · Cited by 15
Yuen, S. C., Zhu, H., & Leung, S.-W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00209 · Cited by 16
“A loss of DPP6 or FXYD7 is reported to dysregulate neuronal excitation (Hoos et al., 2013; Cacace et al., 2019), while RHOQ is reported to enhance A β oligomerization (Aguilar et al., 2017).”
BackgroundHao, Y., Dong, M., Sun, Y., Duan, X., & Niu, W. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1147757 · Cited by 13
“From another aspect, Aβ might not be the best treatment target in patients with mild or moderate AD, or monoclonal antibodies against Aβ cannot remove an important species of Aβ that plays a contributing role in the pathogenesis of AD (37).”
BackgroundImmunotherapy in Alzheimer’s Disease: Current Status and Future Directions
Vashisth, K., Sharma, S., Ghosh, S., Babu, M. A., Ghosh, S., Iqbal, D., Kamal, M., Almutary, A. G., Jha, S. K., Ojha, S. K., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230603 · Cited by 18
“Similar to clinical studies with bapineuzumab, the first mAb, to target A (cid:2) , which failed to demonstrate any discernible efficacy, phase III clinical trials were conducted for solanezumab, another A (cid:2) targeting mAb, and that also failed to achieve its primary endpoints [41].”
PET/CT/MRI in Clinical Trials of Alzheimer’s Disease
Høilund‐Carlsen, P. F., Alavi, A. A., & Barrio, J. R. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240206 · Cited by 13
Stem cell therapy in Alzheimer’s disease: current status and perspectives
Ou, C.-M., Xue, W.-W., Liu, D., Ma, L., Xie, H.-T., & Ning, K. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1440334 · Cited by 19
Spore powder of Ganoderma lucidum for Alzheimer's disease: A protocol for systematic review
Qin, L.-H., Wang, C., Qin, L., Liang, Y., & Wang, G. (2019) · Medicine · doi:10.1097/md.0000000000014382 · Cited by 16
Jing, J., Zhang, F., Zhao, L., Xie, J., Chen, J., Zhong, R., Zhang, Y., & Dong, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201335 · Cited by 15
Probable Causes of Alzheimer’s Disease
Adams, J. D., Jr. (2021) · Sci · doi:10.3390/sci3010016 · Cited by 14
Potential of astrocytes in targeting therapy for Alzheimer’s disease
Bi, W., Lei, T., Cai, S., Zhang, X., Yang, Y., Xiao, Z., Wang, L., & Du, H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109368 · Cited by 13
Li, B., Li, J., Hao, Y., Xie, P., Yue, S., Wang, S., Zhang, J., & Zhang, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116393 · Cited by 13
Treatments for AD: towards the right target at the right time
van der Flier, W. M., & Tijms, B. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00869-0 · Cited by 13
Moezzi, S.-M.-I., Mozafari, N., Fazel-Hoseini, S.-M., Nadimi-Parashkoohi, S., Abbasi, H., Ashrafi, H., & Azadi, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00637 · Cited by 13
Lifestyle Factors and Alzheimer’s Disease
van Praag, H. (2018) · Brain Plasticity · doi:10.3233/bpl-120418 · Cited by 16
“Sadly, there are no effective treatment options for AD patients, and recent clinical trials have resulted in failure [5].”
Background
Metadata
- Authors
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., Case, M., Dean, R. A., Hake, A., Sundell, K., Poole Hoffmann, V., Carlson, C., Khanna, R., Mintun, M., DeMattos, R., Selzler, K. J., & Siemers, E.
- Affiliations
- Université Toulouse III - Paul Sabatier (FR)
- From the Department of Neurology and Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Columbia University Medical Center, New York (L.S.H.); Gérontopôle, Centre Hospitalier Universitaire Toulouse, Unité Mixte de Recherche INSERM Unité 1027 Université Toulouse III–Paul Sabatier, Toulouse, France (B.V.); Austin Health Continuing Care Clinical Service Unit, Heidelberg, and the University of Melbourne, Melbourne, VIC — both in Australia (M.W.); Fundació ACE, Alzheimer Research...
- Western University (CA)
- Karolinska University Hospital (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-25
- Volume
- 378
- Issue
- 4
- Pages
- 321-330
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2787612390
- Cited by
- 1,049
- References
- 27
- Citations by year
- 2026: 48 · 2025: 93 · 2024: 121 · 2023: 123 · 2022: 136 · 2021: 129 · 2020: 169 · 2019: 136 · 2018: 91
- FWCI
- 90.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- IUScholarWorks (Indiana University) (submittedVersion)
- Publisher
- Funders
- Eli Lilly and Company
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, mild dementia, amyloid-beta, humanized monoclonal antibody, amyloid-beta clearance, cognitive decline, florbetapir PET, cerebral edema, treatment efficacy, amyloid plaques, neurofibrillary tangles
- MeSH terms
- Mental Status and Dementia Tests, Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, Immunotherapy, Infusions, Intravenous, Male, Middle Aged, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, Treatment Failure, Positron-Emission Tomography, Plaque, Amyloid, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.